Teva Pharma (NYSE: TEVA) reported Q3 EPS of $1.35, $0.07 better than the analyst estimate of $1.28. Revenue for the quarter came in at $4.8 billion versus the consensus estimate of $4.75 billion.

Teva Pharma sees FY2015 EPS of $5.40-$5.45, versus prior guidance of $5.15-$5.40 and the consensus of $5.32.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.